4CPS-102 Measurement of health outcomes of pomalidomide, cyclophosphamide and dexamethasone combination in adult patients with relapsed and refractory multiple myeloma. (March 2019)

• Record Type: Journal Article
• Authors: Alarcon-Payer, C; Cano Domínguez, S; Jiménez Morales, A; Ríos Tamayo, R; Jurado Chacón, M
• Is Part Of: European journal of hospital pharmacy. Volume 26(2019)Supplement 1
• Page Start: A116
• Page End: A116
• Publication Date: 2019-03
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2019-eahpconf.251
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Multiple myeloma is a plasma cell malignancy that accounts for 1% of all cancers. Despite available therapies, the disease remains uniformly fatal, and patients who have received prior lenalidomide and bortezomib have a median overall survival of 9 months. Pomalidomide and low-dose dexamethasone (PomDex) is standard treatment for lenalidomide refractory myeloma patients who have received >2 prior therapies. Combination therapy is often used in clinical practice in an attempt to overcome drug/clone resistance. Purpose: To measure health outcomes in the combination of pomalidomide, cyclophosphamide and dexamethasone (PomCyDex) in adult patients with relapsed and refractory multiple myeloma (RRMM). Material and methods: Three-year prospective observational study of 31 cases of RRMM. To measure the health outcomes obtained with the PomCyDex combination in a third-level hospital we used median progression-free survival as the main variable to assess if the combination is effective. Age, number of previous treatment lines and most frequent adverse reactions were also measured. Results: Thirty-one RRMM cases were analysed, (48.3%: women; 51.6%: men). The mean age was 68 years. The health outcomes measured in our clinical practice were as follows: 38.7% of the patients were treated with PomCyDex in the third line, 12.9% in the fourth line, 25.8% in the fifth line, 19.3% in the sixth line and 3.2% in the seventh line. The mean number of PomCyDex cycles received was nine. The median PFS was 9.9 months. The PomCydex combination was shown to improve PFS by an additional 5.9 months compared to PomDex-only patients receiving a 4 month PFS (MM-003). The most frequent adverse reactions observed were neutropaenia (38%), anaemia (11%) and thrombocytopaenia (5%). Conclusion: Health outcomes of the PomCyDex combination are similar to those published by Baz et al 1 and is considered an effective combination. The PomCyDex combination is well tolerated in most patients and is therefore considered a safe treatment. Reference and/or acknowledgements: Baz RC, et al. Blood 2016;127:2561–8. No conflict of interest.